Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

Heerspink, 2016, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications, Circulation, 134, 752, 10.1161/CIRCULATIONAHA.116.021887 Cherney, 2016, The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes, Diabetologia, 59, 1860, 10.1007/s00125-016-4008-2 Barnett, 2014, Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol, 2, 369, 10.1016/S2213-8587(13)70208-0 Fioretto, 2016, Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment, Diabetologia, 59, 2036, 10.1007/s00125-016-4017-1 Petrykiv, 2017, Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function, Clin J Am Soc Nephrol, 12, 751, 10.2215/CJN.10180916 Petrykiv, 2017, The albuminuria lowering response to dapagliflozin is variable and reproducible between individual patients, Diabetes Obes Metab, 10.1111/dom.12936 Heerspink, 2016, Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers, Diabetes Obes Metab, 18, 590, 10.1111/dom.12654 Cherney, 2014, Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation, 129, 587, 10.1161/CIRCULATIONAHA.113.005081 Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 323, 10.1056/NEJMoa1515920 Gansevoort, 2013, Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention, Lancet, 382, 339, 10.1016/S0140-6736(13)60595-4 Matsushita, 2010, Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis, Lancet, 375, 2073, 10.1016/S0140-6736(10)60674-5 van der Velde, 2011, Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts, Kidney Int, 79, 1341, 10.1038/ki.2010.536 Carrero, 2017, Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality, Kidney Int, 91, 244, 10.1016/j.kint.2016.09.037 Heerspink, 2015, Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis, J Am Soc Nephrol, 26, 2055, 10.1681/ASN.2014070688 de Zeeuw, 2004, Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL, Kidney Int, 65, 2309, 10.1111/j.1523-1755.2004.00653.x Zinman, 2015, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 373, 2117, 10.1056/NEJMoa1504720 Fitchett, 2016, Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial, Eur Heart J, 37, 1526, 10.1093/eurheartj/ehv728 Zinman, 2014, Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME), Cardiovasc Diabetol, 13, 102, 10.1186/1475-2840-13-102 Perkins, 2016, No need to sugarcoat the message: is cardiovascular risk reduction from SGLT2 inhibition related to natriuresis?, Am J Kidney Dis, 68, 349, 10.1053/j.ajkd.2016.03.410 Rajasekeran, 2016, Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis, Kidney Int, 89, 524, 10.1016/j.kint.2015.12.038 Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 375, 1834, 10.1056/NEJMoa1607141 Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med, 375, 311, 10.1056/NEJMoa1603827 Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 10.1056/NEJMoa1611925 Mosenzon, 2017, Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial, Diabetes Care, 40, 69, 10.2337/dc16-0621 Cornel, 2016, Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS, Diabetes Care, 39, 2304, 10.2337/dc16-1415 de Boer, 2016, Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC study, Clin J Am Soc Nephrol, 11, 1969, 10.2215/CJN.02870316 Heerspink, 2016, Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial, Diabetes Obes Metab, 18, 169, 10.1111/dom.12600 Ruggenenti, 2011, Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial, J Hypertens, 29, 207, 10.1097/HJH.0b013e32834069bd Heerspink, 2017, Canagliflozin slows progression of renal function decline independently of glycemic effects, J Am Soc Nephrol, 28, 368, 10.1681/ASN.2016030278 Gembardt, 2014, The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension, Am J Physiol Renal Physiol, 307, F317, 10.1152/ajprenal.00145.2014 Ishibashi, 2016, Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation, Horm Metab Res, 48, 191 Skrtic, 2015, Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy, Curr Opin Nephrol Hypertens, 24, 96, 10.1097/MNH.0000000000000084 Takakura, 2016, Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats, Life Sci, 147, 125, 10.1016/j.lfs.2016.01.042 Harper, 2015, Policies, guidelines and consensus statements: pharmacologic management of type 2 diabetes-2015 interim update, Can J Diabetes, 39, 250, 10.1016/j.jcjd.2015.05.009 Ponikowski, 2016, Eur J Heart Fail, 18, 891, 10.1002/ejhf.592 Karalliedde, 2010, Proteinuria in diabetes: bystander or pathway to cardiorenal disease?, J Am Soc Nephrol, 21, 2020, 10.1681/ASN.2010030250 Glassock, 2010, Is the presence of microalbuminuria a relevant marker of kidney disease?, Curr Hypertens Rep, 12, 364, 10.1007/s11906-010-0133-3 Parving, 2009, Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design, Nephrol Dial Transplant, 24, 1663, 10.1093/ndt/gfn721 Kropelin, 2016, Determining the optimal protocol for measuring an albuminuria class transition in clinical trials in diabetic kidney disease, J Am Soc Nephrol, 27, 3405, 10.1681/ASN.2015101150 Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161